Advertisement

Investigational New Drugs

, Volume 9, Issue 4, pp 353–356 | Cite as

Phase II study of amonafide in advanced pancreatic adenocarcinoma

  • Kaye Linke
  • Richard Pazdur
  • James L. Abbruzzese
  • Jaffer A. Ajani
  • Rodger Winn
  • James E. Bradof
  • Karen Daugherty
  • Bernard Levin
Clinical Studies

Abstract

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

key words

amonafide pancreatic carcinoma phase II 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Silverberg E, Boring CC, Squires TS: Cancer statistics, 1990. CA-A Cancer Journal for Clinicians 40:9–26, 1990Google Scholar
  2. 2.
    Loehrer PJ, Williams SD, Einhorn LH, Ansari R: Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3:367–372, 1985Google Scholar
  3. 3.
    Smith FP, Hoth DF, Levin B, Karlin DA, MacDonald JS, Woolley PV, Schein PS: 5-fluorouracil, Adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014–2018, 1980Google Scholar
  4. 4.
    Smith FP, Priego V, Lokey L, Neete J, Byrne P, McVie G, Woolley PV, Schein PS: Phase II evaluation of hexamethylmelamine + FAM (Hexa-FAM) in advanced measurable pancreatic cancer (Abstr). Proc Am Soc Clin Oncol 2:126, 1983Google Scholar
  5. 5.
    Smith FP, Rustgi VK, Schertz G, Woolley PV, Schein PS: Phase II study of 5FU, doxorubicin and mitomycin-C (FAM) and chlorozotocin in advanced measurable pancreatic cancer. Cancer Treat Rep 66:2095–2096, 1982Google Scholar
  6. 6.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAMA 253:2061–2067, 1985CrossRefPubMedGoogle Scholar
  7. 7.
    Zimmerman SE, Smith FP, Schein PS: Chemotherapy of pancreatic carcinoma. Cancer 47:1724–1728, 1981Google Scholar
  8. 8.
    Bukowski RM: Randomized comparison of 5FU and mitomycin-C versus 5FU, mitomycin-C and streptozotocin in pancreatic adenocarcinoma. A Southwest Oncology Group Study (Abstr). Proc Am Soc Clin Oncol 1:453, 1981Google Scholar
  9. 9.
    Oster MW, Theologides A, Cooper MR, Rafla S, Hutchinson JL, Holland JH, Anbar D: 5-fluorouracil + Adriamycin + mitomycin-C versus 5-fluorouracil + streptozotocin + mitomycin-C in advanced pancreatic cancer (Abstr). Proc Am Soc Clin Oncol 2:90, 1982Google Scholar
  10. 10.
    The Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol 4:1794–1798, 1986Google Scholar
  11. 11.
    Waring MJ, Gonzalez A, Jimenez A, Vazquez D: Intercalative binding to DNA of antitumor drugs derived from 3-nitro-1,8-naphthalic acid. Nucleic Acid Res 7:217–230, 1979Google Scholar
  12. 12.
    Andersson BS, Bakic M, Beran M, Silberman LE, Newman RA, Zwelling LA: In vitro toxicity and DNA cleaving capacity of Benzisoquinolonedione (nafidimide NSC 308847) in human leukemia. Cancer Res 47:1040–1044, 1987Google Scholar
  13. 13.
    Sinha BK, Strong J, Gibson NEW, Kalyanaraman B: Mechanism of DNA strand breaks by amonafide, a imide derivative of 3-nitro-1,8-naphthalic acid. Biochem Pharmacol 34:3845–3852, 1985Google Scholar
  14. 14.
    Clinical Brochure. Amonafide. Division of Cancer Treatment. The National Cancer Institute, Bethesda, Maryland, March, 1988Google Scholar
  15. 15.
    Garcia-Gancedo A, Gil-Fernandez C, Vilas P, Perez S, Paez E, Rodriguez F, Brana MF, Roldan CM: Imide derivatives of 3-nitro-1,8-naphthalic acid: their inhibitory activity against DNA viruses. Arch Virol 74:157–165, 1982Google Scholar
  16. 16.
    Garcia-Gancedo A, Gil C, Roldan CM, Perez S, Vilas P: Antiviral action of benzo(de)isoquinoline-1,3-diones. Chemotherapy 25:83–90, 1979Google Scholar
  17. 17.
    Brana MF, Sanz AM, Castellano JM: Synthesis and cytostatic activity of benzo(de)isoquinolin-1,3-diones. Structure-activity relationships. Eur J Med Chem 16:207–212, 1981Google Scholar
  18. 18.
    Paull KD, Nasr M, Narayanan VL: Computer assisted structure-activity correlations. Evaluation of benzo(de)isoquinolin-1,3-diones and related compounds as antitumor agents. Arzneim Forsch 34:1243–1246, 1984Google Scholar
  19. 19.
    Lu K, Legha S, Savaraj N, Krakoff I, Newman R: Clinical pharmacology of nafidimide (Abstr). Proc Am Soc Clin Oncol 5:53, 1986Google Scholar
  20. 20.
    Legha SS, Ring S, Raber MN, Felder TB, Newman R, Krakoff I: Phase I clinical investigation of benzisoquinolinedione (Amonafide NSC 308847). Cancer Treat Rep 71:1165–1169, 1987Google Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Kaye Linke
    • 1
  • Richard Pazdur
    • 1
  • James L. Abbruzzese
    • 1
  • Jaffer A. Ajani
    • 1
  • Rodger Winn
    • 1
  • James E. Bradof
    • 1
  • Karen Daugherty
    • 1
  • Bernard Levin
    • 1
  1. 1.Sections of Digestive Diseases and Gastrointestinal Oncology, and the Community Oncology Program, Division of MedicineThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations